Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational study on novel natural compound inhibitor targeting IDH1_R132H.

Aging - 7 Jul 2022

Zhou Baolin, Yang Fang, Qin Lei, Kuai Jun, Yang Lu, Zhang Lanfang, Sun Peisheng, Li Guangpeng, Wang Xinhui

Abstract excerpt

Isocitrate dehydrogenases (IDH) catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. IDH1 mutation has been reported in various tumors especially Cholangiocarcinoma, while the IDH1_R132H is reported to be the most common mutation of IDH1. IDH1_R132H inhibitors are effective anti-cancer drugs and have shown significant therapeutic effects in clinical. In this study, two novel natural compounds...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35802554
DOI: 10.18632/aging.204162
PMCID: PMC9320544

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational study on novel natural compound inhibitor targeting IDH1_R132H.PMID 35802554Read ↗

In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma.Semantic proximity Read ↗

Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.Semantic proximity Read ↗

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.Semantic proximity Read ↗

An integrative computational approach for the identification of dual inhibitors of isocitrate dehydrogenase 1 and 2 from phytocompounds of Phyllantus amarus.Semantic proximity Read ↗

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Semantic proximity Read ↗

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy.Semantic proximity Read ↗

Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.Semantic proximity Read ↗

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapySemantic proximity Read ↗

Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.Semantic proximity Read ↗

Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach.Semantic proximity Read ↗

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.Semantic proximity Read ↗

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.